NASDAQ:DTIL
Precision Biosciences Inc.
Precision Biosciences Inc.'s revenue fell 50.1% in fiscal 2025 to $34.3M while operating margin fell to −152.2%. Free cash flow was −$65.9M, −192.4% of revenue, and the diluted share count rose 86.3%.Summary generated from Precision Biosciences Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$34.3M
Revenue growth−50.1%
Revenue, 5-yr CAGR+7.1%
Gross marginn/a
Operating margin−152.2%
Net margin−133.4%
ROICn/a
Return on equity−61.5%
Debt / equityn/a
Free cash flow−$65.9M
FCF margin−192.4%
Share count change+86.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 116 | 25 | 49 | 69 | 34 |
| Operating income | −39 | −62 | −44 | −26 | −52 |
| Net income | −31 | −112 | −61 | 7 | −46 |
| Free cash flow | −16 | −49 | −86 | −59 | −66 |
Recent filings
- 4Insider transaction report
Sep 30, 2026 - 4Insider transaction report
Sep 29, 2026 - 8-KRegulation FD disclosure
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jul 27, 2026 - 8-KRegulation FD disclosure
Jul 1, 2026 - 8-KEntry into a material agreement
Jun 16, 2026